A research team is claiming is has identified as many as 15 biomarkers that distinguish prostate cancer from benign prostate disease and healthy tissue with an astonishing accuracy of up to 90 percent.
Oxford Gene Technology presented the results of its work at the recent American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development as an abstract.
Currently, prostate cancer diagnosis relies on a rectal examination and tests for a single biomarker, known as PSA (prostate-specific antigen), which has a much lower accuracy percentage.
CANCER TYPE(S)
Prostate cancer
TREATMENT TYPE(S)
Diagnosis and preventitive therapy
WHERE WAS THIS STUDY PUBLISHED?
This study was presented as an abstract at the 2010 American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development. It has not yet been published in a peer-reviewed scientific journal; until then its findings should be considered preliminary only.
Source(s)
AACR Abstract #A6
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
